HOLX — Hologic, Inc.

Hologic Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $1.024 billion, a slight increase of 0.4% year-over-year, exceeding guidance by $14 million.
• Non-GAAP EPS: $1.08, up 1.9% year-over-year, and $0.01 above guidance.
• Operating Margin: 30.1%, down 110 basis points year-over-year.
• Diagnostics Revenue: $448.9 million, up 0.9% (2.9% organically, excluding COVID-19).
• Breast Health Revenue: $365.2 million, down 5.8% (10.8% organically).
• Surgical Revenue: $178.4 million, up 6.3% (1.2% organically).
• Skeletal Revenue: $31.3 million, up 62.1%, driven by resumed shipping of DEXA models.
• Operating Cash Flow: $343 million, with $1.88 billion in cash and short-term investments.

2. Strategic Updates and Business Highlights

• Breast Health: Focus on improving commercial execution and launching new products, including the AI solution Genius AI Detection PRO. The acquisition of Endomagnetics contributed nearly $20 million in revenue.
• Diagnostics: Strong growth in molecular diagnostics, particularly with BV, CV/TV assays. The rollout of the Genius digital cytology platform is receiving positive feedback.
• Surgical: International growth driven by new market expansions and established reimbursements.
• Tariff Mitigation: Successfully reduced anticipated tariff impacts from $20-$25 million per quarter to $10-$12 million through supply chain adjustments.

3. Forward Guidance and Outlook

• Q4 2025 Guidance: Expected revenue of $1.03 billion to $1.04 billion and non-GAAP EPS of $1.09 to $1.12, indicating mid-single-digit revenue growth and high single-digit EPS growth.
• Fiscal 2026 Outlook: Anticipating mid-single-digit organic revenue growth, with expectations for the Breast Health business to return to growth and continued strength in Diagnostics and Surgical segments.

4. Bad News, Challenges, or Points of Concern

• Breast Health Decline: Revenue declined year-over-year, although sequential growth was noted. The business faced challenges with longer gantry replacement cycles.
• China Market Impact: Significant decline in revenue from China, down more than 50% year-over-year, due to geopolitical issues and funding cuts for HIV testing.
• Tariff Headwinds: Continued tariff impacts are expected to affect gross margins, despite mitigation efforts.
• Product Discontinuation: The discontinuation of the Fluoroscan product may impact revenue in the Skeletal division.

5. Notable Q&A Insights

• Growth Dynamics: Analysts inquired about potential headwinds or tailwinds impacting growth into fiscal 2026, with management highlighting challenges in the first half related to China and HIV.
• M&A Strategy: Management indicated a focus on share buybacks and smaller acquisitions rather than large-scale M&A, emphasizing a patient approach to growth.
• Breast Health Strategy: The restructuring of the sales force and end-of-life strategy for older gantries is expected to yield positive results, with confidence in returning to growth in Q4.
• Genius Cytology: The rollout is seen as a significant workflow change, with positive feedback from customers, although the adoption process is gradual.
• Market Expansion: Management views self-collection for HPV testing as an opportunity to expand the market rather than a threat to existing in-office testing volumes.

This summary encapsulates the key points from Hologic's Q3 2025 earnings call, providing a clear view of the company's financial performance, strategic direction, and outlook for the future.